| I |
Original contributions |
|
Senior authorship / shared senior authorship |
| 1. |
Lorenzen JM, Thum T, Eisenbach GM, Haller H, Kielstein JT.
Conversion from conventional in-centre
thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated
clinical parameters. Int Urol Nephrol. 2011 Feb 27. [Epub ahead of print]
|
| 2. |
Tutarel O, Denecke A, Bode-Böger SM, Martens-Lobenhoffer J, Schieffer B, Westhoff-Bleck M,
Kielstein JT. Symmetrical
Dimethylarginine Outperforms CKD-EPI and MDRD-Derived eGFR for the Assessment of Renal Function
in Patients with Adult Congenital Heart Disease. Kidney Blood Press Res.
2010; 34(1):41-45.
|
| 3. |
Rifai K, Bode-Boeger SM, Martens-Lobenhoffer J, Ernst T, Kretschmer U, Hafer C, Fliser D,
Manns MP, Kielstein JT.
Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma
separation and adsorption. Scand J Gastroenterol. 2010; 45(9):1110-5.
|
| 4. |
David S, Kümpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Böger SM, Kliem V,
Haller H, Kielstein JT.
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
Nephrol Dial Transplant. 2010; 25(8):2571-6.
|
| 5. |
Kümpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, Faulhaber-Walther R,
Kielstein JT. Serum neutrophil gelatinase-associated lipocalin (NGAL) at
inception of renal replacement therapy predicts mortality in critically ill patients with acute
kidney injury. Crit Care. 2010; 14(1):R9.
|
| 6. |
Kümpers P, Hafer C, David S, Hecker H, Fliser D, Lukasz, Kielstein JT,
Faulhaber-Walther R. Angiopoietin-2 in patients requiring renal replacement therapy in the
ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome.
Intensive Care Med. 2010; 36(3):462-70.
|
| 7. |
Lorenzen J, Krämer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H, Fliser D,
Kielstein JT. Circulating
levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk
markers in patients with chronic kidney disease. Eur J Clin Invest. 2010; 40(4):294-300.
|
| 8. |
David S, Kümpers P, Hellpap J, Horn R, Leitolf H, Haller H,
Kielstein JT. Angiopoietin 2 and Cardiovascular Disease in Dialysis and
Kidney Transplantation. Am J Kidney Dis. 2009; 53(5):770-8.
|
| 9. |
Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D,
Kielstein JT. The Hannover Dialysis Outcome study: comparison of standard
versus intensified extended dialysis for treatment of patients with acute kidney injury in the
intensive care unit. Nephrol Dial Transplant. 2009; 24(7):2179-86.
|
| 10. |
David S, Kümpers P, Eisenbach GM, Haller H, Kielstein JT.
Prospective evaluation of an in-centre
conversion from conventional haemodialysis to an intensified nocturnal strategy.
Nephrol Dial Transplant. 2009; 24(7):2232-40.
|
| 11. |
Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Fliser D,
Kielstein JT. Pharmacokinetics of Ertapenem in critically ill patients
with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant.
2009; 24(1):267-71.
PDF
|
| 12. |
Kümpers P, Lukasz A, David S, Horn R, Hafer C, Faulhaber-Walter R, Fliser D, Haller H,
Kielstein JT. Excess
circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical
patients. Crit Care. 2008; 12(6):R147.
|
| 13. |
Czock D, Hüsig-Linde C, Langhoff A, Schöpke T, Hafer C, de Groot K, Swoboda S, Kuse E,
Haller H, Fliser D, Keller F, Kielstein JT. Pharmacokinetics of
moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure
and undergo extended daily dialysis. Clin J Am Soc Nephrol. 2006; 1: 1263-1268.
PDF
|
|
First / equally contributed first authorship |
| 1. |
Kielstein JT, Tolk S, Hafer C, Heiden A, Wiesner O, Kühn C, Hadem J,
Hoeper MM, Fischer S. Effect of acute kidney
injury requiring extended dialysis on 28 day and 1 year survival of patients undergoing
interventional lung assist membrane ventilator treatment. BMC Nephrol. 2011 ;12:15.
|
| 2. |
Lovric S, Kielstein JT, Kayser D, Bröcker V, Becker JU, Hiss M,
Schiffer M, Sommerwerck U, Haller H, Strüber M, Welte T, Gottlieb J. Combination of
everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic
syndrome in lung transplant recipients—a case series. Nephrol Dial Transplant.
2011 Feb 10. [Epub ahead of print]
|
| 3. |
Sorrentino JN, Kielstein JT, Lukasz A, Gohrbandt B, Haller H, Schmidt BM.
High permeability dialysis membrane allows
effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis.
Crit Care Med. 2011; 39(1):184-6.
|
| 4. |
Kielstein JT, Veldink H, Martens-Lobenhoffer J, Haller H, Burg M, Lorenzen
JM, Lichtinghagen R, Bode-Böger SM, Kliem V.
SDMA is an early marker of change in GFR after
living-related kidney donation. Nephrol Dial Transplant. 2011; 26(1):324-8.
|
| 5. |
Kielstein JT, Engbers C, Bode-Boger SM, Martens-Lobenhoffer J, Haller H,
Joukhadar C, Traunmüller F, Knitsch W, Hafer C, Burkhardt O. Dosing of daptomycin in
intensive care unit patients with acute kidney injury undergoing extended dialysis – a
pharmacokinetic study. Nephrol Dial Transplant. 2010; 25(5):1537-41.
|
| 6. |
Kielstein JT, Hesse G, Bahr MJ, Tsikas D, Terkamp C, Martens-Lobenhoffer
J, Haller H, Manns MP, Panning B, Bode-Boger SM, Gebel M. Procedure-related pulmonary hypertension
in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection (PEI) – Role
of ethanol, hemolysis, ADMA and the nitric oxide (NO) system. Critical Care Medicine.
2009; 37(4):1483-5.
|
| 7. |
Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D.
Two cardiovascular risk factors in one?
Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with
27,000 participants. Kidney and Blood Pressure Research. 2008; 31(4):259-67.
PDF
|
| 8. |
Peter C, Kielstein JT, Clarke-Katzenberg R, Adams MC, Pitsiouni M,
Kambham N, Karimi MA, Kengatharan KM, Cooke JP. A novel bioluminescent tumor model of human
renal cancer cell lines: an in vitro and in vivo characterization. J Urology 2007;
177(6):2342-2346.
|
| 9. |
Kalousova M, Kielstein JT, Hodkova M, Zima T, Dusilova-Sulkova S,
Martens-Lobenhoffer J, Bode-Böger SM. No Benefit of Hemodiafiltration over Hemodialysis
in Lowering Elevated Levels of Asymmetric Dimethylarginine in ESRD Patients. Blood Purif.
2006; 24(5):439-444.
PDF
|
| 10. |
Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A,
Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Böger SM. ADMA increases
arterial stiffness and decreases cerebral blood flow in human. Stroke. 2006;
37(8):2024-9.
PDF
|
| 11. |
Kielstein JT, Salpeter S, Bode-Böger SM, Cooke JP, Fliser D.
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis.
Nephrol Dial Transplant. 2006; 21(9):2446-51.
|
| 12. |
Kielstein JT, Czock D, Schöpke T, Hafer C, Bode-Böger SM,
Kuse E, Keller F, Fliser D. Pharmacokinetics and total elimination of meropenem and vancomycin
in intensive care unit patients undergoing extended daily dialysis. Crit Care Med. 2006;
34: 51-56.
PDF
|
| 13. |
Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A,
Fliser D, Hoeper MM. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.
Arterioscler Thromb Vasc Biol. 2005; 25: 1414-1418.
|
| 14. |
Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D.
Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a
randomized controlled study. Am J Kidney Dis. 2004; 43: 342-349.
|
| 15. |
Kielstein JT, Böger RH, Bode-Böger SM, Martens-Lobenhoffer J,
Lonnemann G, Frölich JC, Haller H, Fliser D. Low dialysance of asymmetric dimethylarginine
(ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol.
2004; 62: 295-300.
PDF
|
| 16. |
Kielstein JT, Simmel S, Bode-Böger SM, Roth HJ, Schmidt-Gayk H,
Haller H, Fliser D. Subpressor dose Asymmetric dimethylarginine modulates renal blood flow
through nitric oxide synthase inhibition. Kidney Blood Press Res. 2004; 27: 143-147.
PDF
|
| 17. |
Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D,
Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide
synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;
109: 172-177.
PDF
|
| 18. |
Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D. Increased
resistin blood levels are not associated with insulin resistance in patients with renal disease.
Am J Kidney Dis. 2003; 42: 62-66.
|
| 19. |
Kielstein JT, Bode-Böger SM, Klein G, Graf S, Haller H, Fliser D.
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure.
Eur J Clin Invest. 2003; 33: 370-375.
PDF
|
| 20. |
Kielstein JT, Bode-Böger SM, Frölich JC, Ritz E, Haller H,
Fliser D. Asymmetric dimethylarginine (ADMA), blood pressure and renal perfusion in elderly
subjects. Circulation. 2003; 107: 1891-1895.
PDF
|
| 21. |
Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller
H, Ritz E, Fliser D. Marked increase of asymmetric dimethylarginine in patients with incipient
primary chronic renal disease. J Am Soc Nephrol. 2002; 13: 170-176.
PDF
|
| 22. |
Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey
M, Koch KM, Frölich JC. Asymmetric dimethylarginine plasma concentrations differ in
patients with end-stage renal disease: relationship to treatment method and atherosclerotic
disease. J Am Soc Nephrol. 1999; 10: 594-600.
PDF
|
|
Co-authorship |
| 1. |
Worthmann H, Chen S, Martens-Lobenhoffer J, Li N, Deb M, Tryc AB, Goldbecker A, Dong Q,
Kielstein JT, Bode-Böger SM, Weissenborn K.
High Plasma Dimethylarginine Levels are Associated
with Adverse Clinical Outcome After Stroke. J Atheroscler Thromb. 2011 May 12.
[Epub ahead of print]
|
| 2. |
Beutel G, Wiesner O, Eder M, Hafer C, Schneider AS, Kielstein JT, Kuehn C,
Heim A, Ganzenmueller T, Kreipe H, Haverich A, Tecklenburg A, Ganser A, Welte T, Hoeper MM.
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009
influenza A (H1N1) infection. Crit Care. 2011 Mar 2;15(2):R80. [Epub ahead of print]
|
| 3. |
Schiffer L, Kielstein JT, Haubitz M, Lührs H, Witte T, Haller H,
Kümpers P, Schiffer M. Elevation of serum
CXCL13 in SLE as well as in sepsis. Lupus. 2010 Nov 15. [Epub ahead of print]
|
| 4. |
Lorenzen JM, David S, Richter A, de Groot K, Kielstein JT, Haller H,
Thum T, Fliser D. TLR-4+ peripheral blood monocytes and cardiovascular events in patients with
chronic kidney disease--a prospective follow-up study. Nephrol Dial Transplant.
2011 Jan 14. [Epub ahead of print]
|
| 5. |
Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO,
Winkelmann BR, März W. Symmetrical and
Asymmetrical Dimethylarginine as Predictors for Mortality in Patients Referred for Coronary
Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2011,
57(1):112-21.
|
| 6. |
Lovric S, Lukasz A, Hafer C, Kielstein JT, Haubitz M, Haller H,
Kümpers P. Removal of elevated circulating
angiopoietin-2 by plasma exchange - A pilot study in critically ill patients with thrombotic
microangiopathy and anti-glomerular basement membrane disease. Thromb Haemost. 2010,
104(5):1038-43.
|
| 7. |
Lorenzen JM, Hafer C, Faulhaber-Walter R, Kümpers P, Kielstein JT,
Haller H, Fliser D. Osteopontin predicts survival
in critically ill patients with acute kidney injury. Nephrol Dial Transplant.
2010 Aug 23. [Epub ahead of print]
|
| 8. |
Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, Kielstein JT,
Cooke JP. Asymmetric dimethylarginine correlates
with measures of disease severity, major adverse cardiovascular events and all-cause mortality in
patients with peripheral arterial disease. Vasc Med. 2010; 15(4):267-74.
|
| 9. |
Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT,
Haller H, Fliser D. Endothelial progenitor cells
and cardiovascular events in patients with chronic kidney disease--a prospective follow-up
study. PLoS One. 2010, 8;5(7):e11477.
|
| 10. |
Lorenzen JM, Neunh&ooml;ffer H, David S, Kielstein JT, Haller H, Fliser D.
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential
hypertension-Results from the EUTOPIA trial. Atherosclerosis. 2010, 209(1):184-8.
|
| 11. |
Trebst C, Reising A, Kielstein JT, Hafer C, Stangel M.
Plasma Exchange Therapy in Steroid-Unresponsive
Relapses in Patients with Multiple Sclerosis. Blood Purif. 2009; 28(2):108-115.
|
| 12. |
David S, Kümpers P, Lukasz A, Kielstein JT, Haller H, Fliser D.
Circulating angiopoietin-2 in essential
hypertension: relation to atherosclerosis, vascular inflammation, and treatment with
olmesartan/pravastatin. J Hypertens. 2009, [Epub ahead of print]
|
| 13. |
Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, Kümpers
P. Circulating angiopoietin-1 and
angiopoietin-2 in critically ill patients: development and clinical application of two new
immunoassays. Crit Care. 2008;12(4):R94.
|
| 14. |
Martens-Lobenhoffer J, Kielstein JT, Oye C, Bode-Böger SM.
Validated high performance liquid
chromatography-UV detection method for the determination of daptomycin in human plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):546-50.
|
| 15. |
Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and
progression of CKD. Kidney Int. 2007;72:S21-S25.
|
| 16. |
Menne J, Park JK, Agrawal R, Lindschau C, Kielstein JT, Kirsch T, Marx
A, Müller D, Bahlmann FH, Meier M, Bode-Böger SM, Haller H, Fliser D. Cellular and
molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
FASEB J 2006; 20:994-996.
PDF
|
| 17. |
Bode-Böger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J,
Breithardt G, Fobker M, Reinecke H. Symmetrical dimethylarginine: a new combined parameter for
renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17:
1128-1134.
PDF
|
| 18. |
Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM,
Haller H, Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease. The
mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461.
|
| 19. |
Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel S, Tager M,
Bode-B&ooml;ger SM. Erythropoietin increases asymmetric dimethylarginine (ADMA) in endothelial
cells – role of Dimethylarginine Dimethylaminohydrolase (DDAH). J Am Soc Nephrol. 2005;
16: 892-898.
|
| 20. |
Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser
D. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with
kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16:
1091-1098.
|
| 21. |
Woywodt A, Herrmann A, Kielstein JT, Haller H, Haubitz M, Purnhagen H.
A novel multimedia tool to improve bedside teaching of cardiac auscultation.
Postgrad Med J. 2004; 80:355-357.
|
| 22. |
Kaiser T, Hermann A, Kielstein JT, Wittke S, Bartel S, Krebs R,
Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Weissinger EM, Fliser D, Mischak H.
Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in
dialysis fluids. J Chromatogr A. 2003; 1013: 157-1571.
|
| 23. |
Terkamp C, Kirchner G, Wedemeyer J, Dettmer A, Kielstein JT, Reindell H,
Bleck J, Manns M, Gebel M. Simulation of abdomen sonography. Evaluation of a new ultrasound
simulator. Ultraschall Med 2003; 24: 239-244.
|
| 24. |
Bode-Böger SM, Böger RH, Kielstein JT, Löffler M,
Schäffer J, Frölich JC. Role of endogenous nitric oxide in circadian blood pressure
regulation in healthy humans and in patients with hypertension or atherosclerosis.
J Investig Med. 2000; 48: 125-132.
|
| 25. |
Widjaja A, Kielstein JT, Horn R, von zur Mühlen A, Kliem V, Brabant
G. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage
renal disease. Nephrol Dial Transplant. 2000; 15: 846-850.
|
| II |
Editorials, Reviews, Case reports, Letter |
|
Editorials |
| 1. |
Kielstein JT, Fliser D. Do
sea stars have low ADMA levels? High ADMA and low EPC count--duo infernal for the kidney.
Nephrol Dial Transplant. 2010; 25(10):3138-41.
|
| 2. |
Kielstein JT, Kielstein A. ADMA and the brain: an unfolding story.
Am J Hypertens. 2009; 22(3):240.
|
| 3. |
Kielstein JT, Sydow K. Glomerular filtration and coronary flow: is ADMA
the faucet regulating both? Am J Hypertens. 2008; 21(6):601-2.
|
| 4. |
Kielstein JT, Tsao PS. From Zanius to ADMA: ADMA - a
new "adipocytokine" and its potential role in metabolic syndrome. J Nephrol. 2007;20:515-7.
|
| 5. |
Kielstein JT, Fliser D. Lowering Asymmetric Dimethylarginine - A New
Mechanism Mediating the Renoprotective Effects of Renin-Angiotensin System Inhibitors in
Proteinuric Patients? Blood Purif. 2007; 25:324-326.
|
| 6. |
Kielstein JT, Zoccali C. A new perspective for the treatment of renal
diseases? J Am Soc Nephrol 2007:18:1365-1367.
|
| 7. |
Kielstein JT, Cooke JP. Should we measure ADMA in patients with coronary
artery disease? Clin Chem. 2007; 53:161-163.
|
|
Reviews |
| 1. |
Kielstein JT, Burkhardt O.
Dosing of Antibiotics in Critically Ill Patients
Undergoing Renal Replacement Therapy. Curr Pharm Biotechnol. 2011 May 10.
[Epub ahead of print]
|
| 2. |
Kielstein JT, Schiffer M. Nephrogenic systemic fibrosis: A rare disease
with grave consequences. Internist (Berl.) 2010;51(1):39-44.
|
| 3. |
Burkhardt O & Kielstein JT.
A simplified three-times weekly daptomycin dosing
regimen for chronic hemodialysis patients. Expert Rev Anti Infect Ther. 2010;8(1):11-4.
|
| 4. |
Kielstein JT, Fliser D, Veldink H.
Asymmetric dimethylarginine and symmetric
dimethylarginine: axis of evil or useful alliance? Semin Dial 2009;22(4):346-50.
|
| 5. |
Kielstein JT. Dosis der Nierenersatztherapie beim akuten Nierenversagen.
Dtsch Med Wochenschr. 2009;134(34-35):1697-9.
|
| 6. |
Kielstein JT, Zoccali C.
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic
kidney disease. Curr Opin Nephrol Hypertens 2008;17(6):609-15.
|
| 7. |
Kielstein JT, Fliser D. Das Akute Nierenversagen - Extrakorporale Therapie.
Internist. 2007; 48(8):786-794.
|
| 8. |
Kielstein JT & Fliser D. The past presence and future of ADMA in
Nephrology. Nephrol Ther. 2007; 3(2):47-54.
|
| 9. |
Fliser D, Kielstein JT, Menne J. Insulin resistance in renal disease.
Contrib Nephrol 2006; 151:203-211.
|
| 10. |
Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the
pathogenesis of renal disease? Curr Opin Nephrol Hypertens. 2006; 15: 314-320.
PDF
|
| 11. |
Fliser D, Kielstein JT. Technology Insight: treatment of renal failure in
the intensive care unit with extended dialysis. Nature Clinical Practice Nephrology. 2006;
2: 32-39.
PDF
|
| 12. |
Kielstein JT, Tsikas D, Fliser D. Effects of Asymmetric dimethylarginine
(ADMA) infusion in humans. Eur J Clin Pharmacol. 2005; 14: 1-6.
|
| 13. |
Kielstein JT, Zoccali C. Asymmetyric Dimethylarginine: A cardiovascular
risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005; 46: 186-202.
|
| 14. |
Fliser D, Kielstein JT. A single-pass batch dialysis system: an ideal
dialysis method for the patient in intensive care with acute renal failure.
Curr Opin Crit Care 2004, 10: 483-488.
|
| 15. |
Fliser D, Kielstein JT, Haller H, Bode-Böger SM. Asymmetric
dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int Suppl. 2003;
(Suppl 84): S37-S40.
PDF
|
| 16. |
Kielstein JT, Bode-Böger SM, Haller H, Fliser D. Functional changes
in the ageing kidney: is there a role for asymmetric dimethylarginine?
Nephrol Dial Transplant. 2003; 18: 1245-1248.
PDF
|
| 17. |
Kielstein JT, Frölich JC, Haller H, Fliser D.
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with
renal disease? Nephrol Dial Transplant. 2001; 16: 1742-1745.
PDF
|
| 18. |
Kielstein JT, Bode-Böger SM, Frölich JC, Haller H, Böger
RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
Kidney Int Suppl. 2001; (Suppl 78): S9-S13.
|
|
Case reports |
| 1. |
Eden G, Busch M, Kühn-Velten WN, Schneider A, Kielstein JT. Successful
treatment of life-threatening pentoxifylline intoxication by high-flux hemodialysis .
Clin Nephrol. 2011; 75(2):171-3.
|
| 2. |
Chatzikyrkou C, Hamwi I, Clajus C, Becker J, Hafer C, Kielstein JT.
Biopsy proven acute interstitial nephritis after
treatment with moxifloxacin. BMC Nephrol. 2010, 23;11:19.
|
| 3. |
Laurisch S, Jaedtke M, Demir R, Sorrentino SA, Kielstein JT, Rennekampff
HO, Vogt PM, Meyer GP, Fuchs M, Klein G, Drexler H, Schieffer B, Napp LC.
[Allopurinol induced hypersensitivity syndrome
resulting in death] Med Klin (Munich). 2010; 105(4):262-6.
|
| 4. |
Bahte SK, Bertram A, Burkhardt O, Martens-Lobenhoffer J, Goedecke V, Bode-Böger SM, Hiss M,
Kielstein JT. Therapeutic
serum concentrations of daptomycin after intraperitoneal administration in a patient with
peritoneal dialysis-associated peritonitis. J Antimicrob Chemother. 2010; 65(6):1312-4.
|
| 5. |
Burkhardt O, Thon S, Burhenne J, Welte T, Kielstein JT.
Sulphobutylether-beta-cyclodextrin accumulation
in critically ill patients with acute kidney injury treated with intravenous voriconazole under
extended daily dialysis. Int J Antimicrob Agents. 2010;36(1):93-4.
|
| 6. |
Lorenzen JM, Schoenenberger E, Hafer C, Hoeper M, Kielstein JT.
Failed rescue therapy with rapamycin after
paraquat intoxication. Clin Toxicol (Phila). 2010;48(1):84-6.
|
| 7. |
Lovric S, Becker JU, Kayser D, Wagner A, Haubitz M, Kielstein JT.
Fish, flesh and a good red herring: a case of
ascending upper limb infection in a renal transplant patient. Clin Nephrol.
2009; 72(5):402-4.
|
| 8. |
David S, Merscher S, Schmidt-Guertler H, Kielstein JT, Kirchhoff T, Meier
M. A bitter pill to swallow. Clin Nephrol. 2009; 72(4):319-2.
|
| 9. |
Clajus C, Spiegel J, Bröcker V, Chatzikyrkou C, Kielstein JT.
Minimal change nephrotic syndrome in an 82 year
old patient following a tetanus-diphteria-poliomyelitis-vaccination. BMC Nephrology.
2009; 5; 10:21.
|
| 10. |
Burkhardt O, Kaever V, Burhenne H, Kielstein JT.
Extended daily dialysis does not affect the
pharmacokinetics of anidulafungin. Int J Antimicrob Agents. 2009; 34(3):282-3.
|
| 11. |
Burkhardt O, Ellis S, Burhenne H, Kaever V, Hadem J, Kielstein JT, Welte T.
High caspofungin levels in alveolar cells of
a lung transplant patient with suspected pulmonary aspergillosis. Int J Antimicrob
Agents. 2009; 34(5):491-2.
|
| 12. |
Kielstein JT, Lorenzen J, Kaever V, Burhenne H, Broll, M, Hafer C,
Burkhardt O. Risk of underdosing of ampicillin/sulbactam in patients with acute kidney injury
undergoing extended daily dialysis—a single case. Nephrol Dial Transplant. 2009;
24(7):2283-5.
|
| 13. |
Goedecke VA, Clajus C, Burkhardt O, Martens-Lobenhoffer J, Bode-Boger SM,
Kielstein JT, Hiss M. Pharmacokinetics and dialysate levels of daptomycin
given intravenously in a peritoneal dialysis patient. Scand J Infect Dis. 2008; 15:1-3.
|
| 14. |
Kielstein JT, Martens-Lobenhoffer J, Vollmer J, Bode-Böger SM.
L-Arginine, ADMA, SDMA, creatinine, MDRD formula – detour to renal function testing.
J Nephrol. 2008; 21(6):959-61.
|
| 15. |
Clajus B, Becker JU, Stichtenoth DO, Wortmann J, Schwarz A, Kielstein JT.
Acute kidney injury due to deferoxamine in a renal transplant patient.
Nephrol Dial Transplant. 2008, 23:1061-1064.
|
| 16. |
Burkhardt O, Joukhadar C, Traunmüller F, Hadem J, Welte T,
Kielstein JT. Elimination of Daptomycin in a patient with acute renal
failure undergoing extended daily dialysis. Journal of Antimicrobial Chemotherapy.
2008; 61:224-5.
|
| 17. |
Kielstein JT, Stadler M, Czock D, Keller F, Hertenstein B, Radermacher J.
Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.
Eur J Haematology. 2005; 74: 533-534.
PDF
|
| 18. |
Kielstein JT, Linnenweber S, Schoepke T, Fliser D. One for all-a multi-use
dialysis system for effective treatment of severe thallium intoxication.
Kidney Blood Press Res. 2004; 27: 197-199.
|
| 19. |
Kielstein JT, Woywodt A, Schumann G, Haller H, Fliser D. Efficiency of
high-flux hemodialysis in the treatment of valproic acid intoxication.
J Toxicol Clin Toxicol. 2003; 41: 873-876.
|
| 20. |
Kielstein JT, Schwarz A, Arnavaz A, Sehlberg O, Emrich HM, Fliser D.
High-flux hemodialysis-an effective alternative to hemoperfusion in the treatment of carbamazepine
intoxication. Clin Nephrol. 2002; 57: 484-486.
|
| 21. |
Woywodt A, Kielstein JT, Haller H. An uncommon cause of metabolic acidosis
in a haemodialysis patient. Nephrol Dial Transplant. 2002; 17: 929-930.
|
| 22. |
Kielstein JT, Abou-Rebyeh F, Hafer C, Haller H, Fliser D. Right-sided chest
pain at the onset of haemodialysis. Nephrol Dial Transplant. 2001; 16: 1493-1495.
|
| 23. |
Kielstein JT, Helmchen U, Netzer KO, Weber M, Haller H, Floege J.
Conversion of Goodpasture's syndrome into membranous glomerulonephritis.
Nephrol Dial Transplant. 2001; 16: 2082-2085.
|
| 24. |
Woywodt A, Kielstein JT, Winkler M. Clinical picture: Subphrenic abscess
and rupture of the spleen. Lancet. 2001; 358: 875.
|
| 25. |
Kielstein JT, Termühlen L, Sohn J, Kliem V. Minimal change nephrotic
syndrome in a 65-year-old patient following influenza vaccination. Clin Nephrol. 2000;
54: 246-248.
|
|
Letter |
| 1. |
Nave H, Beutel G, Kielstein JT.
Obesity-related immunodeficiency in patients
with pandemic influenza H1N1. Lancet Infect Dis. 2011, 11(1):14-5.
|
| 2. |
Kielstein JT, Schmidt BMW. High dose allopurinol in patients with stable
angina pectoris. Lancet. 2010, 367:1298-1299.
|
| 3. |
Burkhardt O, Kumar V, Schmidt S, Kielstein JT, Welte T, Derendorf H.
Underdosing of ertapenem in critically ill
patients with pneumonia confirmed by Monte Carlo simulations. Int J Antimicrob Agents.
2010; 35(1):96-7.
|
| 4. |
Kielstein JT, Burkhardt O, Bode-Boeger SM.
Dose matters: dose of antibiotics in the
critically ill patient depends on the dose of renal replacement therapy. Crit Care Med
2009; 237(8):2491.
|
| 5. |
Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T.
Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.
Int J Antimicrob Agents. 2009; 34(1):101-2.
|
| 6. |
Kielstein JT, Sydow K, Thum T. Tilarginine in patients with acute
myocardial infarction and cardiogenic shock. JAMA. 2007; 298(9):971.
|
| 7. |
Kielstein JT, Woywodt A, Salpeter SR. Letter by Kielstein et al regarding
article, "High-dose allopurinol improves endothelial function by profoundly reducing vascular
oxidative stress and not by lowering uric acid". Circulation. 2007; 8:115(18):e450-1.
|
| 8. |
Kielstein JT, Peter C, Adams MC. Cigarettes and ADMA: The Smoke Hasn't
Cleared Yet. Hypertension 2006; 177:2342-2346.
|
| 9. |
Kielstein JT, Cooke JP, Zoccali C. Letter regarding article "Renal
Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure."
Circulation 2006; 114: e242.
|
| 10. |
Kielstein JT, Cooke JP. Arginine Metabolism, Pulmonary Hypertension,
and Sickle Cell Disease. JAMA. 2005; 294: 2432-2432.
|
| 11. |
Tsikas D, Frölich JC, Kielstein JT. Nitric oxide synthesis in
chronic renal failure. Are plasma S-nitrosothiol levels elevated? Clin Chim Acta 2004;
339: 195-197. PDF
|